^
Association details:
| Biomarker: | HER-2 underexpression |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Halaven (eribulin mesylate) (Microtubule inhibitor, CBP inhibitor, β-catenin inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy of eribulin mesylate in HER2-low and HER2-0 metastatic breast cancer (MBC): Results from an analysis of two phase 3 studies
Published date:
11/22/2022
Excerpt:
In this post hoc unplanned analysis, we analyzed data from two pivotal phase 3 studies (Studies 305 and 301) comparing eribulin…Patients with HER2-low or HER2-0 BC showed trends toward benefit with eribulin treatment...In this post hoc analysis, treatment with eribulin demonstrated trends toward improved OS, PFS, and ORR compared with chemotherapy controls in patients with HER2-low or HER2-0 MBC.
Source:
Title:
181P - Efficacy of eribulin mesylate in HER2-low metastatic breast cancer (MBC): Results from a pooled analysis of two phase 3 studies
Published date:
05/03/2022
Excerpt:
In this post hoc analysis, we analyzed pooled data from two phase 3 studies (Studies 305 and 301) comparing eribulin with other chemotherapeutic agents (control) in pts with HER2-low MBC….Pts with HER2-low or HER2-0 BC showed trends of improvement in OS, PFS, and ORR with eribulin treatment (Table)....Treatment with eribulin showed trends toward improved OS, PFS, and ORR compared to chemotherapy controls in patients with HER2-low or HER2-0 MBC.
